This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
How to Tap Red-Hot Moderna Stock With ETFs
by Sweta Killa
Moderna shares have surged more than 280% so far this year on the positive development of coronavirus vaccine.
Expect Further Rally in Nasdaq-100 ETFs as Moderna Joins
by Sanghamitra Saha
Moderna shares have gained a whopping 283.6% this year due to successful early-stage clinical trials for COVID-19 vaccine, winning a place on the Nasdaq-100 with the company's sheer success.
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
by Sanghamitra Saha
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
5 Top-Performing ETF Areas of April That Are Up At Least 25%
by Sanghamitra Saha
These ETF areas showered gains in the lockdown-infected April.
5 High-Beta ETFs Available at a Bargain
by Sanghamitra Saha
As the U.S. economy reopens, Wall Street may remain charged up, benefiting high-beta ETFs. Investors can tap those with cheaper valuation.
A Guide to Biotech ETF Investing
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.
Biotech ETFs Surge on a Flurry of Positive News
by Sweta Killa
The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.
Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
Why These Innovative Biotech ETFs Are Soaring
by Neena Mishra
Strong M&A activity has sent shares of many small, innovative biotech companies surging
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
Health Day Checkup of Medical ETFs: 5 Top Picks
by Sanghamitra Saha
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
A Spread of Top-Ranked ETFs That Crushed the Market in Q1
by Sweta Killa
We are presenting a bunch of top performing ETFs of the first quarter with a solid Zacks ETF Rank #1 or 2 which are expected to outperform in the quarter ahead.
Trump Proposes 2020 Budget: ETFs to Top & Flop
by Sweta Killa
Here are the key takeaways from the proposed 2020 budget and their expected impact on ETFs.
Trade Optimism & Earnings Effect: 5 Hot ETF Charts
by Sweta Killa
We have highlighted five best ETFs that buoyed on the combination of trade optimism and decent earnings.
Top ETF Stories of February
by Sanghamitra Saha
Inside the top ETF events of the month of February.
5 ETFs You Can't Help Falling in Love With
by Sweta Killa
As bulls once again fall in love with Wall Street this year, several ETFs have shown strong resiliency and a solid relationship with investors, gaining in double digits.
What's Behind the Biotech ETF Rally to Start 2019?
by Sanghamitra Saha
Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.
5 Beaten-Down ETFs & Stocks on Sale
by Sweta Killa
We have highlighted five solid picks from both the ETF and the stock worlds that were in red over the past week but have a solid upside potential.